Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies

Laurence J.N. Cooper, Zaid Al-Kadhimi, David DiGiusto, Michael Kalos, David Colcher, Andrew Raubitschek, Steve J. Forman, Michael C. Jensen

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalBlood Cells, Molecules, and Diseases
Volume33
Issue number1
DOIs
StatePublished - 2004
Externally publishedYes

Keywords

  • Leukemia
  • T cell
  • Toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies'. Together they form a unique fingerprint.

  • Cite this